Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses treating male pattern baldness with topical products containing Saw Palmetto extract. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

A 22-year-old is experiencing hair loss, particularly fuzzy hair in the front, and is concerned about male pattern baldness. Treatments mentioned include Propecia (finasteride), minoxidil, PRP treatments, dermarolling, peppermint oil, and apple cider vinegar.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

The user is experiencing severe hair loss after surgery and stress, with thinning all over the head, including the sides and neck. They are unsure if it's due to DUPA or alopecia areata incognita, and doctors have not observed miniaturization.

Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

A person feels intense shame and self-hatred due to baldness and poor self-image, affecting their confidence and social interactions. Suggestions include therapy, exercise, braces, hair transplants, and using finasteride.

The conversation discusses using S5 plus cream (Spironolactone, Alfatradiol, and Tempol) as an alternative to finasteride for hair loss, with concerns about its effectiveness and potential systemic absorption. The original poster already uses 5% minoxidil and is seeking alternatives due to fears of finasteride's side effects.

The conversation reassures a woman concerned about thinning hair on her crown, suggesting her hair appears normal and not thinning. Some users recommend prenatal vitamins for hair health, while others attribute the appearance to contrast between dark hair and a pale scalp.

A user with scalp psoriasis and hair loss is hesitant to use topical minoxidil and finasteride due to concerns about psoriasis and potential side effects. They are considering alternatives like pumpkin seed and saw palmetto.

User has been using topical finasteride and minoxidil since May, previously used a spray version since January. They are seeing vellus hairs and have added weekly microneedling to their routine.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

The user is experiencing hair regrowth in small clusters using oral minoxidil, oral finasteride, a red light cap, and Nizoral 2% shampoo. They are hopeful for continued improvement and thicker hair.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

User experienced hair loss due to anorexia and stress, leading to a difficult journey with wigs and self-esteem. Hair regrowth occurred with spironolactone, but recent hair loss returned, causing uncertainty and emotional struggles.

A 21-year-old woman diagnosed with male pattern baldness (MPB) who is considering treatments such as spironolactone, minoxidil and finasteride to address her hair loss. The user also discusses potential solutions for concealing the appearance of her thinning hair, such as wigs or haircuts.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

A 34-year-old woman is experiencing diffuse hair loss and irregular periods, possibly due to long-term spironolactone use. She is considering minoxidil and finasteride for treatment and seeking medical advice for androgenic alopecia and hormonal imbalances.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

A user shared progress pictures showing improvement in PCOS-related hair loss after six months of using topical minoxidil, dermarolling 0.5mm weekly, and taking biotin gummies. They expressed happiness about the appearance of new baby hairs.